Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro

Translated title of the contribution: Progress in treatment by percutaneous coronary intervention: The stent of the future

Takashi Muramatsu, Yoshinobu Onuma, Yao Jun Zhang, Christos V. Bourantas, Alexander Kharlamov, Roberto Diletti, Vasim Farooq, Bill D. Gogas, Scot Garg, Hector M. García-García, Yukio Ozaki, Patrick W. Serruys

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers - stent thrombosis - has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction. This has prompted the development of newer generation drug-eluting stents with biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. This update article presents the current status of these new technologies and highlights their future perspectives in interventional cardiology.

Original languageSpanish
Pages (from-to)483-496
Number of pages14
JournalRevista Espanola de Cardiologia
Volume66
Issue number6
DOIs
Publication statusPublished - 01-06-2013

Fingerprint

Drug-Eluting Stents
Percutaneous Coronary Intervention
Stents
Polymers
Thrombosis
Safety
Delayed Hypersensitivity
Cardiology
Prostheses and Implants
Blood Vessels
Coronary Artery Disease
Coronary Vessels
Clinical Trials
Inflammation
Technology

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Muramatsu, T., Onuma, Y., Zhang, Y. J., Bourantas, C. V., Kharlamov, A., Diletti, R., ... Serruys, P. W. (2013). Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro. Revista Espanola de Cardiologia, 66(6), 483-496. https://doi.org/10.1016/j.recesp.2012.12.009
Muramatsu, Takashi ; Onuma, Yoshinobu ; Zhang, Yao Jun ; Bourantas, Christos V. ; Kharlamov, Alexander ; Diletti, Roberto ; Farooq, Vasim ; Gogas, Bill D. ; Garg, Scot ; García-García, Hector M. ; Ozaki, Yukio ; Serruys, Patrick W. / Avances en el tratamiento mediante intervención coronaria percutánea : el stent del futuro. In: Revista Espanola de Cardiologia. 2013 ; Vol. 66, No. 6. pp. 483-496.
@article{f79d6055122842f5b099cb3a279fff44,
title = "Avances en el tratamiento mediante intervenci{\'o}n coronaria percut{\'a}nea: el stent del futuro",
abstract = "First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers - stent thrombosis - has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction. This has prompted the development of newer generation drug-eluting stents with biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. This update article presents the current status of these new technologies and highlights their future perspectives in interventional cardiology.",
author = "Takashi Muramatsu and Yoshinobu Onuma and Zhang, {Yao Jun} and Bourantas, {Christos V.} and Alexander Kharlamov and Roberto Diletti and Vasim Farooq and Gogas, {Bill D.} and Scot Garg and Garc{\'i}a-Garc{\'i}a, {Hector M.} and Yukio Ozaki and Serruys, {Patrick W.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.recesp.2012.12.009",
language = "Spanish",
volume = "66",
pages = "483--496",
journal = "Revista Espanola de Cardiologia",
issn = "0300-8932",
publisher = "Ediciones Doyma, S.L.",
number = "6",

}

Muramatsu, T, Onuma, Y, Zhang, YJ, Bourantas, CV, Kharlamov, A, Diletti, R, Farooq, V, Gogas, BD, Garg, S, García-García, HM, Ozaki, Y & Serruys, PW 2013, 'Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro', Revista Espanola de Cardiologia, vol. 66, no. 6, pp. 483-496. https://doi.org/10.1016/j.recesp.2012.12.009

Avances en el tratamiento mediante intervención coronaria percutánea : el stent del futuro. / Muramatsu, Takashi; Onuma, Yoshinobu; Zhang, Yao Jun; Bourantas, Christos V.; Kharlamov, Alexander; Diletti, Roberto; Farooq, Vasim; Gogas, Bill D.; Garg, Scot; García-García, Hector M.; Ozaki, Yukio; Serruys, Patrick W.

In: Revista Espanola de Cardiologia, Vol. 66, No. 6, 01.06.2013, p. 483-496.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Avances en el tratamiento mediante intervención coronaria percutánea

T2 - el stent del futuro

AU - Muramatsu, Takashi

AU - Onuma, Yoshinobu

AU - Zhang, Yao Jun

AU - Bourantas, Christos V.

AU - Kharlamov, Alexander

AU - Diletti, Roberto

AU - Farooq, Vasim

AU - Gogas, Bill D.

AU - Garg, Scot

AU - García-García, Hector M.

AU - Ozaki, Yukio

AU - Serruys, Patrick W.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers - stent thrombosis - has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction. This has prompted the development of newer generation drug-eluting stents with biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. This update article presents the current status of these new technologies and highlights their future perspectives in interventional cardiology.

AB - First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers - stent thrombosis - has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction. This has prompted the development of newer generation drug-eluting stents with biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. This update article presents the current status of these new technologies and highlights their future perspectives in interventional cardiology.

UR - http://www.scopus.com/inward/record.url?scp=84932125127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932125127&partnerID=8YFLogxK

U2 - 10.1016/j.recesp.2012.12.009

DO - 10.1016/j.recesp.2012.12.009

M3 - Article

C2 - 24776051

AN - SCOPUS:84932125127

VL - 66

SP - 483

EP - 496

JO - Revista Espanola de Cardiologia

JF - Revista Espanola de Cardiologia

SN - 0300-8932

IS - 6

ER -